NCT03738228 - Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 7, 2019

Primary Completion Date

May 1, 2022

Study Completion Date

September 16, 2026

Conditions

Cervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell CarcinomaStage IB2 Cervical Cancer AJCC v8Stage II Cervical Cancer AJCC v8Stage IIA Cervical Cancer AJCC v8Stage IIA1 Cervical Cancer AJCC v8Stage IIA2 Cervical Cancer AJCC v8Stage IIB Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8

Interventions

DRUG

Atezolizumab

Given IV

RADIATION

Brachytherapy

Undergo standard of care image guided brachytherapy

DRUG

Cisplatin

Given IV

RADIATION

Radiation Therapy

Undergo standard of care radiation therapy

Trial Locations (16)

10065

Memorial Sloan Kettering Cancer Center, New York

14263

Roswell Park Cancer Institute, Buffalo

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

19107

Thomas Jefferson University Hospital, Philadelphia

30912

Augusta University Medical Center, Augusta

35233

University of Alabama at Birmingham Cancer Center, Birmingham

43210

Ohio State University Comprehensive Cancer Center, Columbus

44195

Cleveland Clinic Foundation, Cleveland

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

53226

Medical College of Wisconsin, Milwaukee

73104

University of Oklahoma Health Sciences Center, Oklahoma City

75390

UT Southwestern/Simmons Cancer Center-Dallas, Dallas

80045

UCHealth University of Colorado Hospital, Aurora

92093

UC San Diego Moores Cancer Center, La Jolla

95817

University of California Davis Comprehensive Cancer Center, Sacramento

02905

Women and Infants Hospital, Providence